Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias
Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs)
1 other identifier
observational
300
1 country
1
Brief Summary
Cancer patients are among the most vulnerable individuals, whose health-related quality of life (HRQOL) may be substantially impacted by the COVID19 pandemic. We want to study how the COVID-19 pandemic influences the life of cancer patients and how these patients cope with the additional distress with the aim to facilitate the development of improved future interventional strategies to maintain resilience and HRQOL
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 23, 2020
CompletedFirst Submitted
Initial submission to the registry
November 30, 2020
CompletedFirst Posted
Study publicly available on registry
December 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2020
CompletedDecember 2, 2020
November 1, 2020
1 month
November 30, 2020
November 30, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Influence of the COVID-19 pandemic on cancer patient's daily life
evaluation via questionnaire
single time
Study Arms (1)
cancer patients
adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms
Interventions
1. 13-item questionnaire about cancer patient's distress and everyday life, 2. EORTC-QLQ-C30
Eligibility Criteria
adult cancer patients, with solid or hematologic malignancies, neither tested positive nor having COVID19 symptoms, with an age over 18 years
You may qualify if:
- Age \> 18 years
- validated hematological or oncological disease
- informed consent
You may not qualify if:
- Age \< 18 years
- Insufficient discernment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical University of Innsbruck
Innsbruck, Tyrol, 6020, Austria
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Reinhard Stauder, M.D.
Medical University of Innsbruck, Anichstraße 35, A-6020 Innsbruck, Austria
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 30, 2020
First Posted
December 2, 2020
Study Start
November 23, 2020
Primary Completion
December 31, 2020
Study Completion
December 31, 2020
Last Updated
December 2, 2020
Record last verified: 2020-11
Data Sharing
- IPD Sharing
- Will not share